CompanyCVKDNasdaqPonte Vedra, FL

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is a late-stage biopharmaceutical company developing 12-lipoxygenase inhibitors for critical care cardiology and orphan cardiovascular conditions.

Stories only

SEC EDGAR ClinicalTrials.gov cadrenal.com

8-KSep 29Latest SEC filing

Sep 29Latest story

September 2026

Cadrenal Therapeutics shareholders back share plan increase, warrant issuance at annual meeting

Sep 29PeopleCadrenal Therapeutics, Inc.

August 2026

Cadrenal reports FDA alignment on Phase 3 design for HIT drug CAD-1005

Aug 31Clinical readoutCadrenal Therapeutics, Inc.

Cadrenal reports Q2 2026 results, launches partnering process for cardiac pipeline

Aug 13Quarterly updateCadrenal Therapeutics, Inc.

July 2026

Cadrenal Therapeutics enters separation agreement with departing CMO Ferguson

Jul 17PeopleCadrenal Therapeutics, Inc.

Cadrenal Therapeutics discloses Form D for completed private placement

Jul 15FinancingCadrenal Therapeutics, Inc.

Cadrenal Therapeutics closes $3 million private placement, warrants could add $5.8 million

Jul 1FinancingCadrenal Therapeutics, Inc.

June 2026

Cadrenal names John Sharp interim CFO, board reshuffles after director resigns

Jun 29PeopleCadrenal Therapeutics, Inc.